GENOMICA SAU is Developing New Wuhan Coronavirus Diagnostic Kit .
Jan 31 2020 .
The Kit being developed by GENOMICA will be commercially available in the next 5-7 weeks, and will have the capacity to simultaneously analyze 96 patient samples in less than 5 hours.
With extensive experience in the detection of respiratory pathogens, the Company is currently marketing a diagnostic kit for the detection of 20 different viruses associated with respiratory diseases, including the three most frequently detected coronaviruses in humans (HCoV-229E, HCoV-OC43 and HCoV-NL63). Coronaviruses are an extended family of viruses that can cause the common cold, but also serious diseases such as Severe Acute Respiratory Syndrome (SARS) and Middle Eastern Respiratory Syndrome (MERS).
GENOMICA opened its subsidiary in Wuhan, China, in January 2018, becoming the first Spanish company to manufacture in vitro molecular diagnostic kits, with a subsidiary in China. At the end of 2019, the Company delivered to its Chinese partner, HuaSin Science, the first automatic, molecular diagnostic kits, based on GENOMICA's CLART® technology, for the analysis of human papillomavirus, and which could be used for the diagnosis of this coronavirus, with the new kit being developed by GENOMICA.
On December 31st, 2019, the World Health Organization (WHO) learned of several cases of severe pneumonia in the Chinese city of Wuhan (Hubei province) due to an unknown virus. On January 7th, 2020, the Chinese authorities identified it as belonging to the family of coronaviruses (2019-nCoV).
The number of confirmed cases of "Wuhan pneumonia" (2019-nCoV) infections since December 31stare increasing dramatically daily. Cases have been confirmed in several countries in Asia (China, Thailand, Japan, Taiwan, Republic of Korea, Japan, Malaysia, Singapore, Vietnam, Nepal, Sri Lanka, Cambodia and United Arab Emirates, Europe (France and Germany), the Americas (USA and Canada) and Oceania (Australia).
Due to this global health emergency, reliable diagnostic tools are needed for a rapid response to provide appropriate treatment to patients and to prevent transmission to other citizens.
Facilitar la Vida al Paciente y Mejorar la Salud : Las Bondades de la Tecnología Sanitaria .
Ana Isabel Jiménez, Directora de I+D de Sylentis (Grupo Pharmamar) Explicó una Innovación Disruptiva en el Campo de la Oftalmología .
Se trata de una Tecnología basada en el RNA del Paciente con Degeneración Macular cuyo Objetivo Final es Facilitar el Tratamiento del Paciente, que Hoy por Hoy es Mediante Inyección y Sylentis Propone unas Gotas que se pueden Aplicar en el Propio Domicilio del Paciente.
...
RETINA
La aplicación de SYL1801 en forma de colirio podría ser una nueva opción
terapéutica para el tratamiento de enfermedades de la retina que cursan con Procesos de Neovascularización, frente a las actuales inyecciones intravítreas.
SYL1801 administrado en gotas reduce la angiogénesis (formación de vasos
sanguíneos) en un modelo animal de neovascularización inducida por láser de
forma similar a agentes anti-VEGF inyectados intravítreamente.
Este año se empezarán los Ensayos Clínicos en Humanos con SYL1801 para el Tratamiento de la Degeneración Macular .
Dr. Cavadas Sobre el Virus ... Parece ser que lo que nos están contando no se este ajustando a la realidad ... :
Expansión , 31 Enero 2020 . R. Martínez .
Los Valores de Pequeño Tamaño Despuntan en Bolsa.
... Fernández-Figares Cree que el Mercado Seguirá Premiando a las Compañías que Presentan una " Historia Interesante ".
Como Ejemplo, el Experto Cita a PharmaMar, que Gana este año en Bolsa el 16,8%.
Recientemente, Juan Ros, de Intermoney, Inició la Cobertura de la Biotecnológica con una Recomendación de Comprar y un Precio Objetivo de 5,1 euros, que Implica un Potencial Alcista del 20%.
El Experto Cree que la Cotización Actual da una Probabilidad de Aprobación a su Compuesto Zepsyre del 60%, Cifra que Ros Considera " Baja ".
...
Curr Drug Targets. 2020 Jan 28 .
Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity, and Genomic Predictors of Drug Response.
Souid S, Aissaoui D, Srairi-Abid N, Essafi-Benkhadir K .
Abstract
The use of predictive biomarkers provides potential individualized cancer therapeutic options to prevent therapy failure as well as serious toxicities. Several recent studies showed that predictive and prognostic biomarkers are a notable personalized strategy to improve patients' care in several cancers. Trabectedin (Yondelis®) is a cytotoxic agent, derived from a marine organism, harbouring a significant antitumor activity against several cancers such as soft tissue sarcoma, ovarian, and breast cancers. Recently and with the advent of molecular genetic testing, BRCA mutational status was found as an important predictor of response to this anticancer drug especially in gynecological cancers. The aim of this updated review is to discuss the mechanisms of action of trabectedin against the well-known cancer hallmarks described until today. We also examined the current advances related to genomic biomarkers that can be used in the future to predict the efficacy of this potent anticancer natural molecule in various gynecological cancers.
